Spur Therapeutics is developing targeted gene therapies that precisely modulate gene expression to halt the progression of chronic conditions such as Gaucher disease, Parkinson's, and certain cardiovascular diseases. By delivering a single dose of genetic medicine, the company aims to transform the treatment landscape for debilitating illnesses, improving patient outcomes and quality of life.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SFounders
Product
Problem
Many chronic conditions, such as Gaucher disease, Parkinson's, adrenomyeloneuropathy (AMN) and certain cardiovascular diseases, currently lack effective treatments that can halt disease progression and require frequent and invasive therapies. Traditional treatments often fail to address the underlying genetic causes of these debilitating illnesses.
Solution
Spur Therapeutics is developing targeted adeno-associated virus (AAV) gene therapies designed to precisely modulate gene expression and address the root causes of chronic diseases. Their approach involves delivering a single dose of genetic medicine to alter the course of disease. By optimizing gene expression and delivery, Spur Therapeutics aims to create life-changing therapies that can halt or reverse disease progression, improving patient outcomes and quality of life. The company's pipeline includes programs targeting Gaucher disease, Parkinson's disease, and AMN, with the goal of expanding to other widespread conditions.
Target Audience
The primary target audience includes patients suffering from chronic genetic conditions such as Gaucher disease, Parkinson's disease, and AMN, as well as the physicians and healthcare providers who treat them.
Features
- AAV-mediated gene therapies for targeted gene expression modulation.
- Programs focused on Gaucher disease (FLT201), Parkinson’s disease (SPR301), and Adrenomyeloneuropathy (SBT101).
- FLT201: Clinical-stage gene therapy candidate for Gaucher Disease, with Phase 1/2 trial data demonstrating positive results.
- SPR301: Gene therapy candidate for GBA1 Parkinson’s Disease, with preclinical data showing dose-dependent reduction of inflammation.
- SBT101: Gene therapy candidate for Adrenomyeloneuropathy (AMN), with preclinical proof-of-concept data published.
- Designed for single-dose administration.